Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2083-2091
Open Access | Times Cited: 396

Showing 1-25 of 396 citing articles:

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 24, pp. 2221-2232
Open Access | Times Cited: 1015
Once-Weekly Semaglutide in Adolescents with Obesity
Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 24, pp. 2245-2257
Open Access | Times Cited: 348
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10402, pp. 613-626
Open Access | Times Cited: 310
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Louis J. Aronne, Naveed Sattar, Deborah B. Horn, et al.
JAMA (2023) Vol. 331, Iss. 1, pp. 38-38
Open Access | Times Cited: 241
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K. Knop, Vanita R. Aroda, Ruben D do Vale, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 705-719
Closed Access | Times Cited: 174
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
Thomas A. Wadden, Ariana M. Chao, Sriram Machineni, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2909-2918
Open Access | Times Cited: 152
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Javed Butler, Sanjiv J. Shah, Mark C. Petrie, et al.
The Lancet (2024) Vol. 403, Iss. 10437, pp. 1635-1648
Open Access | Times Cited: 120
Semaglutide for the treatment of overweight and obesity: A review
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 18-35
Open Access | Times Cited: 106
Excess body weight: Novel insights into its roles in obesity comorbidities
Xiang Zhang, Suki Ha, Harry Cheuk-Hay Lau, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 16-27
Open Access | Times Cited: 103
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 103
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J. Aronne, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2058-2072
Closed Access | Times Cited: 85
The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Preethi Chandrasekaran, Ralf Weiskirchen
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1882-1882
Open Access | Times Cited: 85
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 77
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery
Jessica Mok, Mariam O. Adeleke, Adrian Brown, et al.
JAMA Surgery (2023) Vol. 158, Iss. 10, pp. 1003-1003
Open Access | Times Cited: 70
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 162-173
Closed Access | Times Cited: 59
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 453-473
Open Access | Times Cited: 54
Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity
Satoshi Yoshiji, Guillaume Butler‐Laporte, Tianyuan Lu, et al.
Nature Metabolism (2023) Vol. 5, Iss. 2, pp. 248-264
Open Access | Times Cited: 53
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Sean Wharton, Rachel L. Batterham, Meena Bhatta, et al.
Obesity (2023) Vol. 31, Iss. 3, pp. 703-715
Open Access | Times Cited: 49
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Patricia J. Rodriguez, Brianna M. Goodwin Cartwright, Samuel Gratzl, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 9, pp. 1056-1056
Open Access | Times Cited: 42
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 41
Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff, Carel W. le Roux, Adam Stefański, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 38
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Yiming Mu, Xiao-lei Bao, Freddy G. Eliaschewitz, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 184-195
Closed Access | Times Cited: 36
Medications for Obesity
Kimberly A. Gudzune, Robert F. Kushner
JAMA (2024) Vol. 332, Iss. 7, pp. 571-571
Closed Access | Times Cited: 35
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 29
Page 1 - Next Page

Scroll to top